Infinity Natural Resources, Inc. Class A INR 深 沪
交易中 09-23 09:57:31 美东时间
13.1078
+0.078
+0.60%
华盛通- 最 高13.17
- 今 开13.01
- 成交量 8124股
- 最 低 13.01
- 昨 收 13.03
- 总市值 8.31亿
- 52周最高 19.585
- 市盈率 静 14.72
- 换手率 0.01%
- 52周最低 11.13
- 委 比 -4.53%
- 总股本 6342.23万
- 历史最高 107.87
- 量 比 0.51
- 振 幅 1.23%
- 历史最低 11.13
- 每 手 1
- 风险率 1.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Infinity Natural Q2 EPS $0.88 Beats $0.79 Estimate, Sales $171.019M Beat $161.761M Estimate
Infinity Natural (NYSE:INR) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.79 by 11.39 percent. This is a 25.42 percent decrease over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $171.019 million w...
08-11 04:22
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
RBC Capital Reiterates Outperform on Infinity Natural, Maintains $27 Price Target
RBC Capital analyst Scott Hanold reiterates Infinity Natural (NYSE:INR) with a Outperform and maintains $27 price target.
07-07 21:04
美股大行评级 | 潜在涨幅43%，慧与获11家大行集体上调目标价；最高300美元，Credo获9家大行集体上调目标价
今日重点评级关注：Ascendiant Capital：维持Genasys"买入"评级，目标价从5.5美元升至6美元；Citizens：维持Abivax"跑赢大市"评级，目标价从131美元升至187美元
06-03 11:17
Citigroup Maintains Buy on Infinity Natural, Lowers Price Target to $20
Citigroup analyst Paul Diamond maintains Infinity Natural (NYSE:INR) with a Buy and lowers the price target from $25 to $20.
06-03 00:13
Infinity Natural Resources shares are trading lower after the company reported mixed Q1 financial results.
Infinity Natural Resources shares are trading lower after the company reported ...
05-13 04:34
Infinity Natural Q1 EPS $(0.35) Misses $0.91 Estimate, Sales $154.872M Beat $142.627M Estimate
Infinity Natural (NYSE:INR) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $0.91 by 138.46 percent. This is a 84.58 percent increase over losses of $(2.27) per share from
05-13 04:22
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
